Oncolytics Biotech Secures New U.S. Patent for Pelareorep Manufacturing Through 2044

On June 16, 2026, Oncolytics Biotech Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a new patent protecting the proprietary commercial manufacturing process for its lead candidate, pelareorep. This new patent is expected to provide intellectual property protection until 2044, ensuring the company's ability to produce the immunotherapy at commercial scale. In addition to the manufacturing patent, the company highlighted that a previously filed method-of-use patent application for pelareorep remains under review. If granted, this application is projected to extend protection through 2046. Oncolytics also disclosed plans to file further patent applications throughout 2026 to strengthen its IP estate across various therapeutic applications and combination therapies. Pelareorep is an intravenously delivered double-stranded RNA immunotherapeutic currently being evaluated in gastrointestinal cancers, including pancreatic and colorectal cancer, where it has received FDA Fast Track designation. The company is currently advancing the program toward potential registration and commercialization.